Burfiralimab
Sponsors
Immunemed Inc., ImmuneMed, Inc.
Conditions
Moderate to Severe Rheumatoid Arthritisrheumatoid arthritis
Phase 2
A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)
Not yet recruitingNCT06306339
Start: 2024-03-31End: 2025-07-31Target: 60Updated: 2024-03-12
A Phase 2a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of
Burfiralimab (hzVSF-v13) added to disease-modifying antirheumatic drugs in patient with moderate to severe Rheumatoid Arthritis
CompletedCTIS2023-507944-35-00
End: 2024-06-11Target: 67Updated: 2024-04-22